A Phase 2, Randomized, Double-Blind, Multicenter Study of Safety, Tolerability, and Efficacy of Debio 1450 vs Vancomycin (IV)/Linezolid (Oral) in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Due to Staphylococcus Sensitive or Resistant to Methicillin

Trial Profile

A Phase 2, Randomized, Double-Blind, Multicenter Study of Safety, Tolerability, and Efficacy of Debio 1450 vs Vancomycin (IV)/Linezolid (Oral) in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Due to Staphylococcus Sensitive or Resistant to Methicillin

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Debio 1450 (Primary) ; Debio 1450 (Primary) ; Linezolid; Vancomycin
  • Indications Bacterial skin diseases; Staphylococcal infections
  • Focus Therapeutic Use
  • Sponsors Debiopharm
  • Most Recent Events

    • 10 Jan 2017 Results published in the Debiopharm Group Media Release
    • 19 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 16 Aug 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top